204 related articles for article (PubMed ID: 28347318)
21. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
Hodges MR; Ople E; Wedel P; Shaw KJ; Jakate A; Kramer WG; Marle SV; van Hoogdalem EJ; Tawadrous M
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0162322. PubMed ID: 36988461
[TBL] [Abstract][Full Text] [Related]
22. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.
Baldoni D; Gutierrez M; Timmer W; Dingemanse J
J Antimicrob Chemother; 2014 Mar; 69(3):706-14. PubMed ID: 24106141
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
24. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
25. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
28. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
29. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.
Alam MZ; Wu X; Mascio C; Chesnel L; Hurdle JG
Antimicrob Agents Chemother; 2015 Sep; 59(9):5165-70. PubMed ID: 26055381
[TBL] [Abstract][Full Text] [Related]
30. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
[TBL] [Abstract][Full Text] [Related]
32. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
Naik H; Steiner DJ; Versavel M; Palmer J; Fong R
Clin Transl Sci; 2021 Jul; 14(4):1272-1279. PubMed ID: 33278330
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
Endres BT; Bassères E; Khaleduzzaman M; Alam MJ; Chesnel L; Garey KW
Antimicrob Agents Chemother; 2016 Jun; 60(6):3519-23. PubMed ID: 27021314
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
35. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
Yoon S; Shin D; Lee H; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
[TBL] [Abstract][Full Text] [Related]
39. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.
Muhammad A; Madhav D; Rawish F; Viveksandeep TC; Albert E; Mollie J; Prateek S
Curr Clin Pharmacol; 2019; 14(3):166-174. PubMed ID: 30924421
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses.
Wach A; Dembowsky K; Dale GE
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
